N/A N=111 Trial of Chronic Pain Self-Management in Clinic or Community for Low-Income Hispanics
Chronic Pain
Primary: Five Times Sit-to-stand (5XSTS) — -4.53; -5.20; -4.18; -6.43 seconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=66 Women Veterans' Substance Abuse Treatment
Substance Use Disorders
Primary: Addiction Severity Index Alcohol Composite — .36; .46; .18; .26 units on a scale
N/A N=33 A Randomized Control Trial of a Simulation-based Curriculum to Enhance Skills in Colonoscopy
Colorectal Cancer
Primary: Transfer of Skills to Clinical Colonoscopy — 72.2; 31.8; 71.9; 32.3 units on a scale
Phase 1 N=54 Staccato Prochlorperazine Single Dose PK Study
Migraine
Primary: Time to Peak (Tmax) — 0.042; 0.033; 0.025; 0.033 hours
N/A N=27 Get Moving and Get Well - Pilot Study
Schizophrenia · Schizoaffective Disorder · Bipolar Disorder
Primary: Change in Behavioral Activation for Depression Scale — 1.3; 1.2; 2.8; 3 units on a scale — p=0.59
N/A N=67 Antibiotic Use Following Distal and Mid-shaft Hypospadias Repair
Hypospadias
Primary: Number of Participants With Urinary Tract Infection — 30; 22; 0; 0 Participants
Phase 1 N=63 To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration
Cystic Fibrosis
Primary: Safety and Tolerability of AZD5634 Following Inhaled Administration of Single-ascending Doses (SAD) (Part A) and Following Administration of Single Inhaled and IV Doses…
Phase 1 N=16 Safety, Tolerability, and Pharmacokinetics of MK-8266 in Elderly Participants With High Blood Pressure (MK-8266-003)
Hypertension
Primary: Number of Participants With Adverse Events (AEs) — 4; 4; 3; 1 Participants
Phase 2 N=66 A Study of Enzastaurin in Participants With Follicular Lymphoma
Lymphoma, Follicular
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 26.4 percentage…
Phase 2 N=10 Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)
Rett Syndrome
Primary: Gait Velocity as Measured by GAITRite System — 62.7; 84.3 cm/sec — p=0.03
Phase 1 N=38 Aldosterone and the Metabolic Syndrome
Metabolic Diseases · Diabetes Mellitus · Endocrine System Diseases
Primary: Plasma Insulin — 75.4; 50.1; 43.5; 114.0 uU/ml
Phase 3 N=192 PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial
Macular Edema · Uveitis
Primary: Proportion of Baseline Central Subfield Thickness Observed at 8 Weeks — .77; .61; .54 proportion of baseline retinal thickness — p=<0.0001
Phase 1 N=328 The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers
ECG Effects
Primary: The Maximum Time-matched Change From Baseline in QT Data Corrected for Heart Rate (QTc), Placebo-corrected, Based on an Individual Correction (QTcI) Method (ΔΔQTcI)…
N/A N=49 CPR Quality Between Flexible Stretcher and Standard Stretcher in OHCA
Out-of-hospital Cardiac Arrest
Primary: Comparison of Percentage of Chest Compression Fraction Between Before- and After-phase Groups — 80.1; 85.2 Percentage of chest compression fraction
N/A N=40 A Comparison of Three Psychoeducational Group Interventions for Veterans With Tinnitus
Tinnitus
Primary: Coping — 34.3; 31.6; 33.2; 30.0 units on a scale